MedTrace Logo

PRediction Of Glycemic RESponse Study

NCT04881019 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1070

Last updated 2025-05-21

No results posted yet for this study

Summary

The purpose of PROGRESS is to engage and intensively monitor 1000 individuals' dietary intake, activity levels, and continuous glucose values over 10 days, link to clinical events out to 3-years, and use that data along with genomic, microbiome, electronic health record (EHR), and other biomarker data to develop a predictive model of individual glucose responses to nutrient intake in individuals with and without type 2 diabetes.

Conditions

  • Glycemic Response

Interventions

DEVICE

Continuous glucose monitoring

Continuous monitoring of blood sugar over a 10-day period.

Sponsors & Collaborators

  • CareEvolution Healthcare Technology

    collaborator UNKNOWN

  • Tempus AI

    collaborator INDUSTRY

  • Scripps Translational Science Institute

    lead OTHER

Principal Investigators

  • Edward Ramos, PhD · Scripps Research

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-08
Primary Completion
2023-09-01
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04881019 on ClinicalTrials.gov